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A critical factor in the proliferation and the metastatic nature of carcinoma 
cells appears to be their resistance to natural programmed cell death 
(apoptosis). However, the molecular mechanisms that enable carcinoma cells to 
become resistant to cell death are unclear. Galectin-3 (Gal-3) is a protein 
that is found at elevated levels in a variety of primary and metastatic tumor 
cells that may play a key role in chemo-resistance and proliferation of 
carcinoma cells. Gal-3 has also been found to play a key role in the 
regulation of common apoptosis commitment pathways. Therefore, we hypothesize 
that peptides, which bind to and inhibit Gal-3 functions, could be used to 
reduce the anti-apoptotic activity of Gal-3 thus increasing the occurrence of 
cell death in carcinoma cells. Two cell lines were cultured, the human breast 
cancer cell line BT549 and a Gal-3-transfected derivative of BT549 (BT549/V). 
After undergoing apoptosis induction with 0.5 M staurosporine, apoptosis 
markers were detected fluorescently using flow cytometry. Our preliminary 
data suggests that, in the absence of anti-galectin-3 peptides, the parent 
BT549 cell line exhibits mitochondrial damage (decrease in mitochondrial 
membrane potential as detected by using MitoTracker Red fluorescence) by 6 
hours of staurosporine treatment, whereas the BT549/V cell line shows little 
change in MitoTracker Red fluorescence even after 8 hours of apoptosis 
induction. A similar pattern is observed when changes in MitoTracker Red 
fluorescence are correlated with changes in phosphatidylserine translocation 
from the inner to outer surface of the plasma membrane. The current data 
suggest that cells transfected with Gal-3 have an increased rate of survival 
after apoptosis induction. In the next phase of this ongoing project, flow 
cytometric studies of changes in membrane permeability and DNA damage in 
parent and galectin-3 transfected BT549 cells will be conducted to further 
define the time-dependent apoptotic response of the BT549 parent versus 
BT549/V cells. Finally, we will observe and compare the effect of anti-Gal-3 
peptides on induction of apoptosis in these two cell lines in order to 
determine if Gal-3 plays a key role in the anti-apoptotic nature of carcinoma 
cells and to test if anti-Gal-3 peptides are efficacious in inhibiting the 
anti-apoptotic functions of Gal-3. 
